From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Tom Winnifrith Bearcast: Malcolm can say what he likes about Ceres but he's wrong & a serious suggestion for Sus Barbatus at Skinbiotherapeutics

By Tom Winnifrith | Friday 1 December 2023


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I start with it being the first day of Advent and a moan about folks starting Christmas far too early. Then onto Skinbiotherapeutics (SBTX), why I am not selling and a suggestion for Stuart Ashman, a serious one, on how he can regain investor trust at a stroke. Then it is Tintra (TNT), Ceres Power (CWR), free speech on this website, Totally (TLY), Vast Resources (VAST) and Rua Life Sciences (RUA),the sponsor of today's ouzo moment.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 17:30:59